Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
13.72
-0.47 (-3.31%)
At close: May 13, 2025, 4:00 PM
13.68
-0.04 (-0.29%)
After-hours: May 13, 2025, 7:44 PM EDT
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2012 - 2019 |
| Gastroenterology Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastroenterology Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| PDT Immunology Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| PDT Immunology Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Metabolic |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Metabolic Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Hematology |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Hematology Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hereditary Angioedema |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hereditary Angioedema Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Genetics and Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Genetics and Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Rare Disease |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | NaN - NaN |
| Japan | 433.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth | -6.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 2,351.71B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 8.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe and Canada | 1,040.90B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe and Canada Growth | 11.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia (ex-Japan) | 281.64B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia (ex-Japan) Growth | 15.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America | 250.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Growth | 41.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Russia / CIS | 89.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Russia / CIS Growth | 32.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographic | 131.32B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographic Growth | 13.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|